One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Regeneron and Sanofi have collaborated on Dupixent since 2007, when they first partnered on the drug’s development and commercialisation. Despite the ongoing lawsuit, Dupixent remains a critical ...
The US Food and Drug Administration (FDA ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG’s Avastin (bevacizumab) and Bristol-Myers Squibb ...
Rumors are spreading all over the place.’ Experts fear the cancellation signals a sidelining of science at federal health ...
13don MSN
Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
Sanofi and Regeneron’s blockbuster biologic ... this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food and Drug Administration (FDA) has accepted a supplemental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback